

Influenza A Virus, A/Brisbane/10/2007 (HA, NA) x A/Puerto Rico/8/1934 (H3N2), Reassortant IVR-147

Catalog No. NR-9695

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor:

Alexander Klimov, Ph.D., Chief, Viral Surveillance and Diagnostic Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia

Manufacturer:

BE Resources

Product Description:

Virus Classification: *Orthomyxoviridae, Influenzavirus A*

Species: Influenza A virus

Reassortant: A/Brisbane/10/2007 (HA, NA) x A/Puerto Rico/8/1934 (H3N2)

Preparation: NR-9695 is a classical reassortant derived from A/Brisbane/10/2007 (H3N2) and A/Puerto Rico/8/1934 (H1N1) viruses. The HA and NA proteins are from A/Brisbane/10/2007 (H3N2).

Comments: Influenza A/Brisbane/10/2007 (H3N2) was originally isolated in Brisbane, Australia on February 6, 2007 from a human nasal swab.¹ The US Food and Drug Administration recommended influenza A/Brisbane/10/2007 (H3N2)-like viruses for use as vaccines during the 2008-2009² and 2009-2010³ influenza seasons. The World Health Organization recommended influenza A/Brisbane/10/2007 (H3N2)-like viruses for use as vaccines during the 2008-2009 and 2009-2010 Northern Hemisphere and the 2008 and 2009 Southern Hemisphere influenza seasons.⁴ Sequence information is available for influenza A virus, A/Brisbane/10/2007 (HA, NA) x A/Puerto Rico/8/1934 (H3N2), Reassortant IVR-147 at the [Influenza Research Database](#).

Influenza A virus, A/Brisbane/10/2007 (HA, NA) x A/Puerto Rico/8/1934 (H1N1), Reassortant IVR-147 is also available as BEI Resources NR-41796. NR-41796 was grown from a different lot of seed virus deposited by the Centers for Disease Control through the Influenza Reagent Resource.

Material Provided:

Each vial contains approximately 1 mL of pooled allantoic fluid from specific pathogen free (SPF) embryonated chicken eggs infected with reassortant influenza A virus, A/Brisbane/10/2007 (HA, NA) x A/Puerto Rico/8/1934 (H3N2).

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

Packaging/Storage:

NR-9695 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

Host: 9- to 11-day-old SPF embryonated chicken eggs

Infection: Embryonated chicken eggs must be candled for viability prior to inoculation

Incubation: 1 to 3 days at 35°C in a humidified chamber

Effect: Hemagglutination activity using chicken red blood cells and allantoic fluid from infected embryonated chicken eggs

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Influenza A Virus, A/Brisbane/10/2007 (HA, NA) x A/Puerto Rico/8/1934 (H3N2), Reassortant IVR-147, NR-9695."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmb15/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this

product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC[®], their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Dr. Alexander Klimov, personal communication.
2. [CDC Prevention and Control of Influenza - 2008 Recommendations](#) (PubMed: [18685555](#))
3. [CDC Prevention and Control of Influenza - 2009 Recommendations](#) (PubMed: [19644442](#))
4. [WHO Recommendations for Influenza Vaccines](#)

ATCC[®] is a trademark of the American Type Culture Collection.

